Skip to main content
. 2023 Jul 6;23:635. doi: 10.1186/s12885-023-11112-w

Fig. 4.

Fig. 4

Pooled partial response (PR) rates of short-term and long-term treatment with atezolizumab plus bevacizumab. A Pooled PR rate of long-term treatment based on Response Evaluation Criteria in Solid Tumors (RECIST). B Pooled PR rate of long-term treatment based on modified RECIST (mRECIST). C Pooled PR rate of short-term treatment based on RECIST. D Pooled PR rate of short-term treatment based on mRECIST